Despite the availability of new technologies and therapies, about half of all patients with diabetes in the United States continue to have inadequate glycemic control ([@B1]). Why? The reasons are multifactorial; however, therapeutic inertia is a major one.

The term "therapeutic inertia" refers to the failure to advance therapy or to de-intensify therapy when appropriate ([@B2]). Why is this important? Many long-term trials show that intensive therapy can have a major impact on cardiovascular morbidity and mortality ([@B3]--[@B5]). Moreover, achieving early glycemic control may generate a positive legacy effect with persistent reduction in microvascular complications, myocardial infarction, and all-cause mortality ([@B3],[@B4]). The EDICT (Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes) trial showed a significant benefit to early combination therapy compared to a stepwise approach in terms of achievement and persistence of therapeutic goals ([@B6]).

Unfortunately, many of us have a "treat to failure" management strategy rather than a "treat to success" approach. In other words, when a patient's A1C becomes inappropriately high, we eventually add a therapeutic agent, and then we wait for the A1C to rise again significantly before we intervene to add another agent. This approach was characterized in a large-scale study of physicians' practices in the real world ([@B7]). For patients with an A1C \>7.5%, it took an average of 1.9 years to intensify treatment by one agent, 7.2 years to add a second agent, and 6.1 years to intensify with a third oral antidiabetic drug ([@B7]). Similarly, when patients are initiated on basal insulin, there is a median wait time of 3.7 years to intensification ([@B8]). The reasons for these long lag times are innumerable and include provider, patient, and health care system issues.

De-intensification of the therapeutic regimen is also an important aspect of therapeutic inertia ([@B9]). We have been taught how and when to add medicines, yet there has been inadequate attention regarding when we should reduce them. At some point, certain therapies may be doing more harm than good. This is especially true in elderly patients for whom aggressive A1C goals and medications such as sulfonylureas may increase the risk of hypoglycemia and untoward consequences.

In November 2018, I had the opportunity to attend an American Diabetes Association (ADA) summit on therapeutic inertia. With more than 130 representatives of various stakeholder groups in attendance, its goal was to develop a disruptive approach to the problem of therapeutic inertia. The day-long meeting included presentations and discussions and a plan to publish a summary of proceedings and develop pragmatic solutions to this crucial problem during the ensuing 3 years.

The underlying larger purpose of the summit, as explained by ADA Chief Executive Officer Tracey D. Brown, MBA, BChE, was "to help patients with diabetes and their families to thrive." This is an admirable goal and one that we can all work toward by actively engaging, partnering, and goal-setting with our patients to assist them in effectively managing their diabetes therapy regimen.

We are eager to learn what the summit produces in terms of initiatives to increase awareness of therapeutic inertia and practical strategies to reduce this significant problem for all of us. Interested parties can keep up with the project as it develops by visiting in the initiative website ([professional.diabetes.org/therapeuticinertia](http://professional.diabetes.org/therapeuticinertia)). The summit agenda and presentations are already available on the website, and a summary of the proceedings will be posted there soon.
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